Author

A. R. Henry

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 12

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 11 Research Focus:host-pathogen & immune response· 10 Organism:human· 6 Research Focus:drug response / drug discovery· 5 Organism:non-human primate· 5 Assay:proteomics· 4 Research Focus:benchmarking· 3 Organism:mouse· 2

Frequent Co-Authors

M. Gagne· 7 shared S. Godbole· 6 shared A. Dodson· 5 shared A. Van Ry· 5 shared F. Laboune· 5 shared L. Pessaint· 5 shared A. Cook· 4 shared B. M. Nagata· 4 shared

Activity by Year

2021-2023 · peak 7/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersImmunology

M. Gagne

Mutual co-authors in cluster

Author profile →

12 papers

Recent·Most cited

Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates

J. I. Moliva, S. F. Andrew, B. J. Flynn, D. A. Wagner, K. E. Foulds, M. Gagne, D. R. Flebbe, E. Lamb, S. Provost, J. Marquez, A. Mychalowych, C. Lorag, C. C. Honeycutt, M. R. Burnett, L. McCormick, , Nason

This study shows a gorilla adenovirus-based vaccine provides durable immunity against SARS-CoV-2 in both airways of non-human primates, with enhanced protection from aerosol delivery and prime-boost regimens.

bioRxiv · Nov 22, 2023 · PreprintImmunology

Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates

M. Gagne, B. J. Flynn, S. F. Andrew, D. R. Flebbe, A. Mychalowych, E. Lamb, M. E. Davis-Gardner, M. R. Burnett, L. A. Serebryannyy, B. C. Lin, L. Pessaint, J.-P. M. Todd, Z. E. Ziff, E. Maule, R. Carroll, , M Suthar

This study shows that mucosal adenoviral-vectored vaccines provide durable protection against XBB.1.16 infection in nonhuman primates, outperforming intramuscular boosting in reducing virus replication in both upper and lower airways.

bioRxiv · Nov 6, 2023 · PreprintImmunology

A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization

J. Misasi, R. R. Wei, L. Wang, A. Pegu, C.-J. Wei, O. Oloniniyi, T. Zhou, J. I. Moliva, B. Zhao, M. Choe, E. S. Yang, Y. Zhang, M. Boruszczak, M. Chen, K. Leung, , N. J. Sullivan

This paper develops multispecific antibodies that neutralize all SARS-CoV-2 variants, including Omicron, by targeting multiple epitopes on the spike protein.

bioRxiv · Jul 29, 2022 · PreprintImmunology

Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones

N. S. Lima, M. Musayev, T. S. Johnston, D. A. Wagner, A. R. Henry, L. Wang, E. S. Yang, Y. Zhang, K. Birungi, W. P. Black, S. O'Dell, S. D. Schmidt, D. Moon, C. G. Lorang, B. Zhao, , P. D. Kwong

The paper examines antibody responses to SARS-CoV-2 variants, finding convergent epitope specificities, V gene usage, and public B cell clones across different variants.

bioRxiv · Mar 28, 2022Immunology

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron

M. Gagne, J. I. Moliva, K. E. Foulds, S. F. Andrew, B. J. Flynn, A. P. Werner, D. A. Wagner, I.-T. Teng, B. C. Lin, C. Moore, N. Jean-Baptiste, R. Carroll, S. L. Foster, M. Patel, M. Ellis, , Naisan

This study compares B cell responses and protection against Omicron after boosting vaccinated macaques with mRNA-1273 or mRNA-Omicron vaccines, finding comparable immunity and protection.

bioRxiv · Feb 3, 2022 · PreprintImmunology

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant

V.-V. Edara, K. E. Manning, M. Ellis, L. Lai, K. M. Moore, S. L. Foster, K. Floyd, M. E. Davis-Gardner, G. Mantus, L. E. Nyhoff, S. Bechnack, G. Alaaeddine, A. Naji, H. Samaha, M. Lee, , M. S. Suthar

This study evaluates the neutralizing activity of mRNA vaccines against the SARS-CoV-2 Omicron variant, showing reduced efficacy after the second dose but improved responses following a third dose.

bioRxiv · Dec 20, 2021Immunology

Durability of immune responses to the BNT162b2 mRNA vaccine

M. Suthar, P. S Arunachalam, M. Hu, N. Reis, M. Trisal, O. Raeber, S. Chinthrajah, M. E. Davis-Gardner, K. Manning, P. Mudvari, S. Godbole, E. Boritz, A. R. Henry, D. Douek, K. Nadeau, , P. Halfmann

This study shows that antibody and T cell responses to the BNT162b2 vaccine wane significantly at 6 months, suggesting a potential need for a third booster dose.

bioRxiv · Sep 30, 2021Immunology

Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates

K. S. Corbett, M. Gagne, D. Wagner, S. O'Connell, S. R. Narpala, D. R. Flebbe, S. F. Andrew, R. L. Davis, B. Flynn, T. S. Johnston, C. Stringham, L. Lai, D. Valentin, A. Van Ry, Z. Flinchbaugh, , A Pekosz

mRNA-1273 boosted nonhuman primates show increased neutralizing antibody responses and protection against SARS-CoV-2 beta variant infection.

bioRxiv · Aug 11, 2021 · PreprintImmunology

A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters

K. M. Wuertz, E. Barkei, W.-h. Chen, E. J. Martinez, I. E. Naouar, L. Jagodzinski, D. Paquin-Proulx, G. D. Gromowski, I. Swafford, A. Ganesh, M. Dong, X. Zeng, P. V. Thomas, R. S. Sankhala, A. Hajduczki, , Vasan

This study evaluates a SARS-CoV-2 spike ferritin nanoparticle vaccine's effectiveness against B.1.1.7 and B.1.351 variants in hamsters, showing protection against disease and viral replication.

bioRxiv · Jun 16, 2021 · PreprintImmunology

Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates

K. S. Corbett, A. Werner, S. O'Connell, M. Gagne, L. Lai, J. Moliva, B. Flynn, A. Choi, M. Koch, K. E. Foulds, S. Andrew, D. Flebbe, E. Lamb, S. T. Nurmukhambetova, S. Provost, , M. Suthar

This study evaluates mRNA-1273 vaccine efficacy against SARS-CoV-2 B.1.351 in nonhuman primates, finding that two doses significantly reduce viral replication in the airways.

bioRxiv · May 21, 2021 · PreprintImmunology

Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant

V.-V. Edara, L. Lai, M. Sahoo, K. Floyd, M. Sibai, D. Solis, M. W. Flowers, L. Hussaini, C. R. Ciric, S. Bechnack, K. Stephens, E. B. Mokhtari, P. Mudvari, A. Creanga, A. Pegu, , M. Suthar

This study assesses neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant in convalescent and vaccinated individuals, finding it is 6.8-fold more resistant but still neutralizable.

bioRxiv · May 9, 2021 · PreprintImmunology

Human antibody immune responses are personalized by selective removal of MHC-II peptide epitopes

M. Gutierrez-Gonzalez, A. S. Fahad, M. Ardito, P. Nanaware, L. Lu, E. Normandin, B. Madan, J. Tivin, E. Coates, A. R. Henry, F. Laboune, B. S. Graham, D. C. Douek, J. E. Ledgerwood, J. R. Mascola, , B. J. DeKosky

The paper shows that MHC-II epitope removal from BCRs correlates with antibody development, T cell help, and long-term serum antibody secretion.

bioRxiv · Jan 15, 2021 · PreprintImmunology